Quince Therapeutics (NASDAQ:QNCX – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.09), Zacks reports. The business had revenue of $0.17 million for the quarter.
Quince Therapeutics Stock Performance
NASDAQ:QNCX opened at $1.40 on Tuesday. The stock has a market capitalization of $61.60 million, a P/E ratio of -1.13 and a beta of 0.71. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45. The firm has a 50 day moving average of $1.49 and a 200-day moving average of $1.44.
Analyst Ratings Changes
Several brokerages have recently weighed in on QNCX. D. Boral Capital decreased their target price on shares of Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday. Oppenheimer initiated coverage on shares of Quince Therapeutics in a research note on Monday. They set an “outperform” rating and a $10.00 price target for the company. Finally, Brookline Capital Management initiated coverage on Quince Therapeutics in a report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 target price for the company. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $8.00.
Quince Therapeutics Company Profile
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Featured Stories
- Five stocks we like better than Quince Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Will CrowdStrike’s FedRAMP Authorization Move CRWD Stock?
- How to Read Stock Charts for Beginners
- Top Utility Stocks Powering Through Volatility
- Top Stocks Investing in 5G Technology
- Small-Caps, Big Buybacks: 3 Stocks With Large Buyback Capacity
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
